Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
TATE and pembrolizumab · 1 trial · 1 indication
From the first day of treatment to death
Per RECIST 1.1 criteria
| Arm | Type | Description |
|---|---|---|
| colorectal cancer | EXPERIMENTAL | metastatic colorectal cancer progressed on at least two lines of chemotherapy |
| NSCLC | EXPERIMENTAL | Liver metastatic NSCLC progressed on immune checkpoint inhibitors and chemotherapy |
| Name | Type | Description |
|---|---|---|
| TATE and pembrolizumab | DRUG | All liver metastatic lesions will be treated with TATE for maximally debulking. Pembrolizumab IV infusion per standard schedule every 3 or 6 weeks until progression or maximally 2 years. |
| TAS-102 pill | DRUG | The comparator of the mCRC arm is TAS-102 at 60 mg BID 5 days per week for 2 weeks then 2 weeks off. |
| Regorafenib Pill | DRUG | As an alternative to TAS-102 per treating physician's discretion. If selected, Regorafenib 160 mg oral daily for 3 weeks on and one week off, every 4 weeks per cycle. Do not take Regoarefnib if taking TAS-102. |
Inclusion Criteria: * Liver metastatic MSS-mCRC or NSCLC without EGFR or AKT mutations * mCRC progressed on at least two lines of standard chemotherapy; or * NSCLC progressed on chemotherapy and an immune checkpoint inhibitor * Measurable disease * ECOG 0-1 * At least 4 weeks from prior chemotherap...